Legal AI startup Harvey closed a $200 million funding round at an $11 billion valuation on March 25, 2026, led by Singapore’s sovereign wealth fund GIC and Sequoia Capital, according to reporting by CNBC and Bloomberg. The round came just months after Harvey was valued at $8 billion in a December 2025 raise, underscoring how quickly valuations are climbing for AI startups that sell autonomous software agents to white-collar professionals rather than consumer chatbots.
From $8 Billion to $11 Billion in Under Four Months
Harvey’s rapid re-up illustrates the pace of the current AI funding cycle. The company had already raised capital three separate times during 2025 alone and has now banked a cumulative $1.2 billion since its founding, according to Harvey’s own disclosures. Existing backers including Andreessen Horowitz, Coatue, Conviction Partners, Kleiner Perkins and early investor Elad Gil all participated again in the March round, a signal that insiders remain convinced the company’s growth trajectory justifies the higher price tag rather than simply defending their position.
The Business Behind the Valuation
Harvey builds AI agents designed to independently complete legal tasks such as contract review, litigation research and due diligence, aiming to embed itself inside law firms and corporate legal departments rather than compete as a general-purpose chatbot. The company said it had reached $190 million in annualized recurring revenue by the end of 2025. Chief executive Winston Weinberg said the fresh capital will go toward expanding Harvey’s autonomous agent capabilities and growing its embedded legal engineering teams, technical staff who work directly inside client firms to customize and deploy the software, an increasingly common go-to-market approach among enterprise AI vendors selling into regulated, high-stakes professions.
Part of a Broader Boom in Vertical AI and Voice Funding
Harvey’s raise sits within a wider surge of venture capital flowing into specialized AI agents and voice-based tools throughout 2026. Healthcare-focused voice AI startup Assort Health separately raised a $120 million Series C at a $1.2 billion valuation, part of a broader wave of funding into companies building AI systems that can place and receive phone calls autonomously, whether to schedule medical appointments, handle customer service or, increasingly, call retail stores on a consumer’s behalf. The conversational and voice AI market has been estimated to have crossed roughly $18 billion in size in 2026, with a large share of Fortune 500 companies now running some form of voice AI in production.
Bulls See a Durable Enterprise Category
Investors backing Harvey and similar vertical AI companies argue that legal, healthcare and other regulated professional-services markets represent some of the most defensible territory for AI startups, because deep domain expertise, compliance requirements and long sales cycles create real barriers that generic chatbot wrappers cannot easily replicate. From that vantage point, an $11 billion valuation for a company already generating $190 million in annualized revenue looks far more grounded than valuations attached to some earlier-stage AI startups with little to no revenue.
Skeptics Question Whether Growth Can Keep Pace
Other observers caution that legal and professional-services AI startups still face an unresolved question: whether law firms and corporate legal departments will keep paying premium prices for AI agents once the technology becomes commoditized, or whether large incumbents like Thomson Reuters and LexisNexis, along with foundation model providers themselves, will squeeze out standalone startups over time. Critics of the broader 2026 AI funding cycle also note that repeated re-ups within months, as seen with Harvey’s move from $8 billion to $11 billion, can reflect investor fear of missing out as much as fundamentals, a dynamic that has drawn comparisons to speculative excess in prior tech cycles.
What Comes Next
Harvey has signaled it plans to keep expanding internationally and deepening its embedded-engineering model, betting that white-glove deployment inside law firms will be harder for rivals to replicate than the underlying AI models themselves. With voice AI and agentic startups like Assort Health also commanding billion-dollar-plus valuations, 2026 is shaping up as the year venture investors decide whether narrow, professionally-focused AI agents can generate the durable revenue needed to justify valuations that, in Harvey’s case, nearly doubled in under half a year.